VINCASAR Drug Patent Profile
✉ Email this page to a colleague
When do Vincasar patents expire, and when can generic versions of Vincasar launch?
Vincasar is a drug marketed by Teva Parenteral and is included in one NDA.
The generic ingredient in VINCASAR is vincristine sulfate. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vincristine sulfate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VINCASAR?
- What are the global sales for VINCASAR?
- What is Average Wholesale Price for VINCASAR?
Summary for VINCASAR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | VINCASAR at DailyMed |
US Patents and Regulatory Information for VINCASAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Parenteral | VINCASAR PFS | vincristine sulfate | INJECTABLE;INJECTION | 071426-001 | Jul 17, 1987 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
